Clinical Trials Logo
  1. Home
  2. Skin Toxicity
  3. NCT03448731

Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA) — DERMIA  

Skin Toxicity Clinical Trial

Official title:
Phase II Clinical Trial of Doxycycline 50 mg or 100 mg Daily for the Prevention of Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy

Clinical Trial Summary

Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with anti-EGFR in combination with chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03448731
Study type Interventional
Source Fundacion CRIS de Investigación para Vencer el Cáncer
Contact
Status Completed
Phase Phase 2
Start date May 10, 2018
Completion date April 6, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04929834 - Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities N/A
Completed NCT04929847 - Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities N/A
Not yet recruiting NCT03606954 - Potency of Topical Corticosteroids in Combination Preparations Phase 4
Completed NCT01976481 - Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27 N/A
Recruiting NCT05109858 - Skin Toxicity by Oncological Therapies
Completed NCT00871429 - Skin Care for Cancer Patients: A Product Satisfaction Survey N/A
Recruiting NCT04469075 - Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields Phase 2
Recruiting NCT04650256 - Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences N/A
Terminated NCT01317433 - Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer N/A
Active, not recruiting NCT03167268 - Panitumumab Skin Toxicity Prevention Trial Phase 2
Recruiting NCT06118047 - Crisaborole Ointment for Skin Toxicity Induced by Cetuximab Phase 2